Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates

Bojkova, Denisa; Widera, Marek; Ciesek, Sandra; Wass, Mark N.; Michaelis, Martin; Cinatl, Jindrich

doi:10.1101/2022.01.03.474773

Cited by 29 publications

(49 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, the higher prevalence of patients with cardiovascular, hepatic, renal disease, and multimorbidity observed in the study cohort may be due to the lower aggressiveness of the Omicron variant 31 , where patients with these comorbidities tended to develop severe COVID-19 when infected by other SARS-CoV-2 strains 32 .…”

Section: Discussionmentioning

confidence: 99%

COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant

Boscolo‐Rizzo

Tirelli

Meloni

et al. 2022

Preprint

View full text Add to dashboard Cite

Background. The aim of this study was to estimate the prevalence of self-reported chemosensory dysfunction in a study cohort of subjects who developed a mild-to-moderate COVID-19 in the period from January 17, 2022 to February 4, 2022 (Omicron proxy period) and compared that with a historical series of patients tested positive for SARS-CoV-2 infection between March and April, 2020 (comparator period). Methods. Prospective study based on the sinonasal outcome tool 22 (SNOT-22), item sense of smell or taste and additional outcomes. Results. Patients characteristics and clinical presentations of COVID-19 were evaluated and compared in 779 patients, 338 of the study cohort and 441 of the historical series. The prevalence of self-reported chemosensory dysfunction during the proxy Omicron period (32.5%; 95% CI, 27.6-37.8) was significantly lower from that during the comparator period (66.9%; 95% CI, 62.3-71.3) (p<.001). 24.6% (95% CI, 20.1-29.5) of patients reported an altered sense of smell during the proxy Omicron period compared to 62.6% (95% CI, 57.9-67.1) during the comparator period (p<.001). Similarly, the prevalence of an altered sense of taste dropped from 57.4% (95% CI, 52.6-62.0) during the comparator period to 26.9% (95% CI, 22.3-32.0) during the proxy Omicron period (p<.001). The severity of chemosensory dysfunction was lower in proxy Omicron period compared to comparator period (p<.001). Conclusions. The prevalence and the severity of COVID-19 associated smell and taste dysfunction has dropped significantly with the advent of the Omicron variant.

show abstract

Section: Discussionmentioning

confidence: 99%

COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant

Boscolo‐Rizzo

Tirelli

Meloni

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The alterations in the Omicron Spike confer resistance to several Spike-targeting monoclonal antibodies (REGN 10933 and 10897) used in the clinic. Other therapeutic agents, however, such as remdesivir, molnupiravir, nirmatrelvir, hydroxycytidine, Paxlovid, Acriflavine (ACF), PF-07321332, and soluble ACE2 remain active against the Omicron VOC at least in vitro ( 91 – 93 ). Several reports indicate that Omicron entry may have shifted toward the TMPRSS2-independent endosomal route ( 77 , 94 , 95 ).…”

Section: Alterations In the Omicron Spike Proteinmentioning

confidence: 99%

Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?

Jung

Kmieć

Koepke

et al. 2022

J Virol

175

140

View full text Add to dashboard Cite

Emerging strains of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19) pandemic, that show increased transmission fitness and/or immune evasion are classified as “variants of concern” (VOCs). Recently, a SARS-CoV-2 variant first identified in November 2021 in South Africa has been recognized as a fifth VOC, termed “Omicron”. What makes this VOC so alarming is the high number of changes, especially in the viral Spike protein, and accumulating evidence for increased transmission efficiency and escape from neutralizing antibodies. In an amazingly short time, the Omicron VOC has outcompeted the previously dominating Delta VOC. However, it seems that the Omicron VOC is overall less pathogenic compared to other SARS-CoV-2 VOCs. Here, we provide an overview of the mutations in the Omicron genome and the resulting changes in viral proteins compared to other SARS-CoV-2 strains and discuss their potential functional consequences.

show abstract

“…Interestingly, the sensitivity of the RADT assay also appeared to increase with time elapsed after symptoms onset, suggesting that vaccine-breakthrough Omicron variant infection may be symptomatic even in the presence of RNA loads below the threshold for viral detection by RADT. Although speculative, this phenomenon may be related to the reduced capability of the Omicron variant to antagonize the host cell interferon response [11] .…”

mentioning

confidence: 99%

Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant

Michelena

Torres

Ramos-García³

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant SARS-CoV-2 isolates

Cited by 29 publications

References 24 publications

COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant

COVID-19-related Smell and Taste Impairment with Widespread Diffusion of SARS-CoV-2 Omicron Variant

Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?

Real-life performance of a COVID-19 rapid antigen detection test targeting the SARS-CoV-2 nucleoprotein for diagnosis of COVID-19 due to the Omicron variant

Contact Info

Product

Resources

About